Arthneeti

Concord Biotech Q2 FY27 Share Price & Earnings Call Analysis

₹1,230.60-2.99% today
Market cap
₹12,874 Cr
P/E
45.28
ROE
12.57%
PEG
58.79
Price to sales
11.58
Debt to equity
0.00
52W high / low
₹1,588 / ₹1,015
Sales growth (5Y)
11.33%
EBITDA margin
36.19%
Net profit margin
22.83%
Promoter holding
44.09%
Sales (last year)
₹1,112 Cr

Incorporated in 1984, Concord Biotech Limited is an India-based R&D-driven biopharma company and manufacturer of fermentation-based APIs across immunosuppressants and oncology.[1]

Guidance scorecard · Q2 FY27 call

What Concord Biotech Ltd's management guided
and where it ranks in Pharmaceuticals & Biotechnology

#7of 83 in
Pharmaceuticals & Biotechnology
Revenue20–40%MarginsUp 2%+CapexPlannedFundraisingWhat management saidOrder bookWhat management said

RevenueQ1 FY27 call

20–40%
  • Concord Biotech targets API revenues of INR 2,200 crores within the next 5 to 6 years without adding new capacity by better utilizing existing units and ramping up specific products like nystatin and fusidic acid.
  • Current capacities show Unit 1 at ~78% utilization and Unit 3 at ~55%-higher than 20-25%, with plans to increase utilization.
  • Future growth relies on oncology and anti-infective products primarily manufactured in Unit 3, with oncology products generating higher revenue despite marginal capacity utilization change.
  • The company expects overall revenue improvement driven by new product launches, increased wallet share, and broader geographic growth.
  • Injectable facility, commercialized last year, is ramping up with sales starting in domestic markets and emerging markets expected next year.

2 more points from Concord Biotech Ltd's call on revenue

Create a free account to keep reading this call

Full Q1 FY27 analysis

MarginsQ1 FY27 call

Up 2%+

See what Concord Biotech Ltd said on margins — free account, 30 seconds.

Full Q1 FY27 analysis

CapexQ1 FY27 call

Planned
  • Concord Biotech is currently not adding capacity for scaling API revenues to INR2,200 crores in 5-6 years, utilizing existing facilities efficiently (Unit 1 at 78%, Unit 2 at 55%, Unit 3 has capacity for pipeline products).
  • Future API capacity expansion will be considered once Unit 3 utilization reaches 80-85%, leveraging available land (only 20-25% used on 160 acres) for brownfield expansion.
  • Potential capex may be required earlier if there’s a need for dedicated fermentation capacities for adjacencies like peptides, veterinary products, etc.
  • The company is exploring both organic and inorganic growth options, including adjacencies in the fermentation space and possible acquisitions.
  • Injectables facility recently commercialized, ramping up sales domestically and targeting emerging markets next year.

2 more points from Concord Biotech Ltd's call on capex

Create a free account to keep reading this call

Full Q1 FY27 analysis

FundraisingQ1 FY27 call

See what Concord Biotech Ltd said on fundraising — free account, 30 seconds.

Full Q1 FY27 analysis

Order bookQ1 FY27 call

  • Concord Biotech has strong business visibility in its pipeline for FY27 and beyond.
  • The company is working on multiple CDMO projects and expects revenue from this segment to increase from 1-2% to a double-digit contribution.
  • Several products, including oncology and anti-infectives, are in advanced stages or pipeline that will drive growth.
  • They continue to engage with innovator customers with a couple of projects progressing well and expected to be in advanced stage or closure by year-end.

2 more points from Concord Biotech Ltd's call on the order book

Create a free account to keep reading this call

Full Q1 FY27 analysis
Full Pharmaceuticals & Biotechnology ranking

Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.

Potential multibaggers · Q2 FY27

Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance

  1. Strong growth
    2
  2. Strong growth
    1
  3. Strong growth
    3
See all potential multibaggersWhere does Concord Biotech Ltd rank?

Portfolio builder

Build your portfolio
from the top-ranked stocks

  1. 1. Pick 3–15 stocks
  2. 2. Choose large, mid or small cap and your sectors
  3. 3. Get a portfolio built from the rankings
Build my portfolio

Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.

Peers

Pharmaceuticals & Biotechnology companies ranked on guidance

#CompanyRevenue guidedMargin guidedMarket capP/E
140%+Up 2%+₹556 Cr22.1
240%+Up 0–2%₹215 Cr22.2
340%+Flat₹16,144 Cr—
440%+Flat₹6,072 Cr48.0
540%+Flat₹40 Cr—
620–40%Up 2%+₹50,220 Cr43.8

Sign up free to see every company in the sector ranking and track Concord Biotech Ltd.

Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology ranking

Concord Biotech Ltd announcements

All announcements →

Financials of Concord Biotech Ltd

Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.

Shareholder Pattern

Concord Biotech Ltd

Shareholding breakup across reporting periods.

Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Promoters +44.08%44.08%44.08%44.08%44.08%44.08%44.08%44.08%44.08%44.08%44.08%44.09%
FIIs +7.00%6.49%7.11%8.10%8.33%9.35%9.10%8.03%7.58%7.79%7.53%7.28%
DIIs +8.40%8.41%10.35%9.89%9.65%9.16%8.85%9.55%9.58%9.22%9.37%10.95%
Public +40.52%41.03%38.46%37.95%37.93%37.41%37.94%38.32%38.75%38.90%39.04%37.68%
No. of Shareholders87,48683,29680,73784,29882,00481,21982,04582,65081,81582,24983,32588,365

Financials of Concord Biotech Ltd

Quarterly Results

Quarter-by-quarter operating performance

Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
Sales +262241319216310244430204247278326261312
Expenses +143135185135174146239143157176204173202
Operating Profit1191061348113798190619110212287110
OPM %45%44%42%38%44%40%44%30%37%37%38%33%35%
Other Income +8811101015914137161310
Interest1000000000000
Depreciation13141413131315181819191818
Profit before tax113100131781339918557869011882102
Tax %25%26%26%25%26%25%23%26%26%25%24%26%26%
Net Profit +847597589974142436368906176
EPS in Rs8.087.139.295.579.437.0813.574.076.016.488.605.857.24

Financials of Concord Biotech Ltd

Profit & Loss

Annual income statement trend

Mar 2015Mar 2016Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales +2392763404365126177138531,0171,2001,0551,177
Expenses +133145212256308289439509585693678755
Operating Profit105131127180205328274344432507377422
OPM %44%48%37%41%40%53%38%40%42%42%36%36%
Other Income +11836173114233534444946
Interest101111653110
Depreciation101018192128505454547475
Profit before tax106129144178213313241320409496351393
Tax %34%33%30%33%21%25%26%26%26%25%25%
Net Profit +7087100118169235179238305373263295
EPS in Rs6.938.619.6111.3216.1522.5017.0722.7629.1335.6525.1728.17
Dividend Payout %22%25%0%21%22%0%3%30%30%25%30%

Financials of Concord Biotech Ltd

Balance Sheet

Capital structure and asset base

Mar 2015Mar 2016Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Sep 2026
Equity Capital9910101010101010101010
Reserves2683295856737619901,0981,2821,5151,8022,0092,076
Borrowings +35362295289623210311
Other Liabilities +5574697111894144191164219216252
Total Liabilities3674486857639411,1831,3131,5151,6992,0342,2372,339
Fixed Assets +104110189230240546573593575795786764
CWIP197031914118741732115179112
Investments424315122919914274138244335488535
Other Assets +202225343285361477592611668854883928
Total Assets3674486857639411,1831,3131,5151,6992,0342,2372,339

Financials of Concord Biotech Ltd

Cash Flows

Operating, investing and financing cash movement

Mar 2015Mar 2016Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity +79155167207246265245264
Cash from Investing Activity +-42-114-195-112-158-155-160-142
Cash from Financing Activity +-37-4331-100-85-99-99-115
Net Cash Flow0-13-4312-147
Free Cash Flow79-1-3752101180134169
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit101%100%74%98%92%85%70%96%

Financials of Concord Biotech Ltd

Ratios

Working capital efficiency and return ratios

Mar 2015Mar 2016Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days165182236133131105119117125159159
Inventory Days276321381310312503434430331286483
Days Payable108129210112201152185190150135150
Cash Conversion Cycle334374407331242456368357306310492
Working Capital Days195209275177159177163153166193231
ROCE %37%25%25%32%21%26%28%28%17%

Guidance history

How Concord Biotech Ltd's guidance has moved, call by call

CallRevenueMarginsCapexFundraisingOrder book
Q1 FY27 call →20–40%Up 2%+Planned——
Q4 FY26 call →10–20%Up 0–2%PlannedNone planned—
Q3 FY26 call →10–20%FlatPlanned—Rising
Q2 FY26 call →20–40%FlatPlanned——

What management guided on each call, newest first. Not investment advice, and not a forecast of returns.

26out of 100

Momentum score · price trend

26 out of 100 — Cooling

Over the past year its share price has done worse than most of the stocks we track.

PeriodShare price changeBetter than … of 1,910 stocks
Last 12 months−15.3%42%
Last 6 months+7.8%64%
Last 3 months−7.5%47%

The price is 52.7% below its all-time high of ₹2,601.1 (20 Sept 2024). Stocks more than 20% below their peak have their score halved, so 52 became 26.

How we calculate it

“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).

The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Concord Biotech Ltd: 0.4 × 42 + 0.4 × 64 + 0.2 × 47 = 52, halved to 26 because the price is more than 20% below its all-time high.

Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.

Full methodology →

This describes only how the share price has moved up to 29 Oct 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.

Continue your research

What Concord Biotech Ltd's management said in earlier quarters

Others in Pharmaceuticals & Biotechnology this season

  • Lincoln Pharmaceuticals Ltd (Q2 FY27)

    2,798.12 Lakhs increase (approximately 17.1% growth) . Key results statement takeaways from Lincoln Pharmaceuticals Ltd's Q2 FY27 results statement — and how it

  • Alivus Life Sciences Ltd (Q2 FY27)

    Q2 FY27 Revenue from Operations: ₹6,820 million, up 16.0% year-on-year (YoY). Key investor presentation takeaways from Alivus Life Sciences Ltd's Q2 FY27 invest

  • Strides Pharma Science Ltd (Q2 FY27)

    Q2FY27 Revenue: ₹14,297 million, up 17.1% YoY (Page 4, 15) . Key investor presentation takeaways from Strides Pharma Science Ltd's Q2 FY27 investor presentation

  • Laurus Labs Ltd (Q2 FY27)

    2Q FY27 Revenue:** ₹2,206 crore, up 33% year-on-year (Y-o-Y) and 9% quarter-on-quarter (Q-o-Q). Key investor presentation takeaways from Laurus Labs Ltd's Q2 FY

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd